Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis

ConclusionsThese results suggest that routine laboratory monitoring of children aged 6 months to<  6 years treated with dupilumab plus topical corticosteroids is not required. Limitations of this study include short study duration, and exclusion of patients with abnormalities in laboratory test results at screening.Clinical Trial RegistrationClinicalTrials.gov: NCT03346434, part B
Source: Pediatric Drugs - Category: Pediatrics Source Type: research